- To the best of the authors’ knowledge, this is the first large-scale, real-world UK study of its kind in this patient population
- The study cohort accounts for approximately 10% of the total adult first-line treated advanced non-small cell lung cancer population in the UK
- Electronic prescribing records (EPRs) were the primary data source used in the study; they are the real-world prescription records for patients who are prescribed systemic anti-cancer therapy
- SVMPharma’s EPR RWE studies are one step ahead of SACT. To learn more, click here
Click here to read the abstract – Lung Cancer.
SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.